Top 5 Stocks to Buy Now
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free IBT Stock Alerts

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 1,060 0.00 (0.00%)
As of 12:03 PM Eastern
Compare

IBT vs. JFJ, IHP, GROW, SDP, and GSS

Should you buy International Biotechnology stock or one of its competitors? MarketBeat compares International Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with International Biotechnology include JPMorgan Japanese (JFJ), IntegraFin (IHP), Molten Ventures (GROW), Schroder Investment Trust - Schroder AsiaPacific Fund (SDP), and Genesis Emerging Markets Fund (GSS). These companies are all part of the "asset management" industry.

How does International Biotechnology compare to JPMorgan Japanese?

International Biotechnology (LON:IBT) and JPMorgan Japanese (LON:JFJ) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.0%. JPMorgan Japanese pays an annual dividend of GBX 8.70 per share and has a dividend yield of 1.1%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. JPMorgan Japanese pays out 5.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, JPMorgan Japanese had 1 more articles in the media than International Biotechnology. MarketBeat recorded 1 mentions for JPMorgan Japanese and 0 mentions for International Biotechnology. International Biotechnology's average media sentiment score of 0.00 equaled JPMorgan Japanese'saverage media sentiment score.

Company Overall Sentiment
International Biotechnology Neutral
JPMorgan Japanese Neutral

International Biotechnology has a beta of 0.52431154, indicating that its stock price is 48% less volatile than the broader market. Comparatively, JPMorgan Japanese has a beta of 0.906, indicating that its stock price is 9% less volatile than the broader market.

6.9% of International Biotechnology shares are owned by institutional investors. Comparatively, 18.9% of JPMorgan Japanese shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by company insiders. Comparatively, 0.1% of JPMorgan Japanese shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

JPMorgan Japanese has a net margin of 96.52% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat JPMorgan Japanese's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
JPMorgan Japanese 96.52%20.00%8.06%

JPMorgan Japanese has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.32£37.91M£241.734.39
JPMorgan Japanese£245.55M5.09£194.81M£149.065.46

Summary

JPMorgan Japanese beats International Biotechnology on 10 of the 14 factors compared between the two stocks.

How does International Biotechnology compare to IntegraFin?

International Biotechnology (LON:IBT) and IntegraFin (LON:IHP) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.0%. IntegraFin pays an annual dividend of GBX 11.30 per share and has a dividend yield of 3.2%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. IntegraFin pays out 59.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

International Biotechnology has a beta of 0.52431154, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, IntegraFin has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

IntegraFin has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.32£37.91M£241.734.39
IntegraFin£165.40M7.03£52.54M£19.1018.43

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 43.3% of IntegraFin shares are held by institutional investors. 1.1% of International Biotechnology shares are held by company insiders. Comparatively, 14.5% of IntegraFin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IntegraFin had 4 more articles in the media than International Biotechnology. MarketBeat recorded 4 mentions for IntegraFin and 0 mentions for International Biotechnology. IntegraFin's average media sentiment score of 1.38 beat International Biotechnology's score of 0.00 indicating that IntegraFin is being referred to more favorably in the news media.

Company Overall Sentiment
International Biotechnology Neutral
IntegraFin Positive

International Biotechnology has a net margin of 82.27% compared to IntegraFin's net margin of 28.60%. IntegraFin's return on equity of 27.60% beat International Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
IntegraFin 28.60%27.60%20.29%

IntegraFin has a consensus target price of GBX 423, indicating a potential upside of 20.17%. Given IntegraFin's stronger consensus rating and higher probable upside, analysts plainly believe IntegraFin is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IntegraFin
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

IntegraFin beats International Biotechnology on 15 of the 18 factors compared between the two stocks.

How does International Biotechnology compare to Molten Ventures?

Molten Ventures (LON:GROW) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Molten Ventures presently has a consensus target price of GBX 638.67, suggesting a potential upside of 11.56%. Given Molten Ventures' stronger consensus rating and higher probable upside, analysts clearly believe Molten Ventures is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

International Biotechnology has lower revenue, but higher earnings than Molten Ventures. International Biotechnology is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molten Ventures£125.60M7.85-£33.58M£61.609.29
International Biotechnology£78.01M4.32£37.91M£241.734.39

In the previous week, Molten Ventures had 2 more articles in the media than International Biotechnology. MarketBeat recorded 2 mentions for Molten Ventures and 0 mentions for International Biotechnology. Molten Ventures' average media sentiment score of 1.55 beat International Biotechnology's score of 0.00 indicating that Molten Ventures is being referred to more favorably in the media.

Company Overall Sentiment
Molten Ventures Very Positive
International Biotechnology Neutral

41.3% of Molten Ventures shares are held by institutional investors. Comparatively, 6.9% of International Biotechnology shares are held by institutional investors. 1.6% of Molten Ventures shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Molten Ventures has a beta of 1.9414055, meaning that its share price is 94% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.52431154, meaning that its share price is 48% less volatile than the broader market.

Molten Ventures has a net margin of 193.06% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
Molten Ventures193.06% 8.51% -3.46%
International Biotechnology 82.27%27.35%3.57%

Summary

Molten Ventures beats International Biotechnology on 12 of the 16 factors compared between the two stocks.

How does International Biotechnology compare to Schroder Investment Trust - Schroder AsiaPacific Fund?

International Biotechnology (LON:IBT) and Schroder Investment Trust - Schroder AsiaPacific Fund (LON:SDP) are both small-cap financial services companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Schroder Investment Trust - Schroder AsiaPacific Fund has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Schroder Investment Trust - Schroder AsiaPacific Fund, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.32£37.91M£241.734.39
Schroder Investment Trust - Schroder AsiaPacific Fund£191.10M5.66£121.21M£135.646.30

International Biotechnology has a beta of 0.52431154, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Schroder Investment Trust - Schroder AsiaPacific Fund has a beta of 1.0276442, suggesting that its share price is 3% more volatile than the broader market.

Schroder Investment Trust - Schroder AsiaPacific Fund has a net margin of 95.12% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Schroder Investment Trust - Schroder AsiaPacific Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Schroder Investment Trust - Schroder AsiaPacific Fund 95.12%20.01%-1.73%

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.0%. Schroder Investment Trust - Schroder AsiaPacific Fund pays an annual dividend of GBX 13 per share and has a dividend yield of 1.5%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Schroder Investment Trust - Schroder AsiaPacific Fund pays out 9.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Schroder Investment Trust - Schroder AsiaPacific Fund had 1 more articles in the media than International Biotechnology. MarketBeat recorded 1 mentions for Schroder Investment Trust - Schroder AsiaPacific Fund and 0 mentions for International Biotechnology. Schroder Investment Trust - Schroder AsiaPacific Fund's average media sentiment score of 1.25 beat International Biotechnology's score of 0.00 indicating that Schroder Investment Trust - Schroder AsiaPacific Fund is being referred to more favorably in the news media.

Company Overall Sentiment
International Biotechnology Neutral
Schroder Investment Trust - Schroder AsiaPacific Fund Positive

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 17.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are held by institutional investors. 1.1% of International Biotechnology shares are held by insiders. Comparatively, 0.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Schroder Investment Trust - Schroder AsiaPacific Fund beats International Biotechnology on 10 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Genesis Emerging Markets Fund?

International Biotechnology (LON:IBT) and Genesis Emerging Markets Fund (LON:GSS) are both small-cap asset management industry companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

6.9% of International Biotechnology shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, International Biotechnology's average media sentiment score of 0.00 equaled Genesis Emerging Markets Fund'saverage media sentiment score.

Company Overall Sentiment
International Biotechnology Neutral
Genesis Emerging Markets Fund Neutral

International Biotechnology has higher earnings, but lower revenue than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.32£37.91M£241.734.39
Genesis Emerging Markets Fund£250.40M0.00N/A£140.70N/A

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.0%. Genesis Emerging Markets Fund pays an annual dividend of GBX 0.17 per share. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Genesis Emerging Markets Fund pays out 0.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

International Biotechnology has a net margin of 82.27% compared to Genesis Emerging Markets Fund's net margin of 0.00%. International Biotechnology's return on equity of 27.35% beat Genesis Emerging Markets Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Genesis Emerging Markets Fund N/A N/A N/A

Summary

International Biotechnology beats Genesis Emerging Markets Fund on 7 of the 10 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

Export
MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£337.38M£2.39B£5.97B£2.77B
Dividend Yield3.09%6.02%5.26%6.16%
P/E Ratio4.3959.7029.08366.66
Price / Sales4.322,054.671,107.4485,978.63
Price / Cash155.7460.3384.9827.87
Price / Book1.381.386.697.76
Net Income£37.91M£265.27M£1.14B£5.89B
7 Day Performance6.00%-0.31%-0.31%-0.72%
1 Month Performance8.38%-0.33%0.42%-1.20%
1 Year Performance79.66%9.07%18.34%65.93%

International Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 1,060
flat		N/A+79.7%£337.38M£78.01M4.39N/A
JFJ
JPMorgan Japanese
N/AGBX 773
+1.7%		N/A+28.0%£1.19B£245.55M5.19N/A
IHP
IntegraFin
4.6397 of 5 stars		GBX 358
+2.1%		GBX 423
+18.2%		+13.7%£1.18B£165.40M18.743,520
GROW
Molten Ventures
3.1198 of 5 stars		GBX 622.50
+0.1%		GBX 599.67
-3.7%		+90.9%£1.07B£125.60M10.1120
SDP
Schroder Investment Trust - Schroder AsiaPacific Fund
N/AGBX 842
+2.1%		N/A+55.8%£1.07B£191.10M6.21N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold Will Hit $4,900
JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...
Investors Alley | Sponsoredtc pixel
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This
Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...
Brownstone Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel